Cover Image
市場調查報告書

腦出血:開發中產品分析

Brain Hemorrhage - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361624
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
腦出血:開發中產品分析 Brain Hemorrhage - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 49 Pages
簡介

本報告提供腦出血的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腦出血概要

治療藥的開發

  • 開發中產品的概要

腦出血:企業開發中的治療藥

腦出血:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

腦出血:企業開發中的產品

腦出血的治療藥開發企業

  • Edge Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fina Biotech
  • MediPost Co., Ltd.
  • Pfizer Inc.
  • Remedy Pharmaceuticals, Inc.

腦出血:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腦出血:最近的開發平台趨勢

腦出血:暫停中的計劃

腦出血:開發中止的產品

腦出血:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8744IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Brain Hemorrhage - Pipeline Review, H2 2016, provides an overview of the Brain Hemorrhage (Central Nervous System) pipeline landscape.

Brain hemorrhage is a type of stroke. It is caused by the bursting of an artery in the brain that leads to localized bleeding in the surrounding tissues. This bleeding kills the brain cells. The common risk factors of brain haemorrhages include head trauma, high blood pressure, aneurysm, blood vessel abnormalities, amyloid angiopathy, blood or bleeding disorders such as hemophilia and sickle cell anemia, liver disease and brain tumors. Symptoms include sudden severe headache, seizures, weakness in an arm or leg, nausea or vomiting, lethargy, changes in vision, tingling or numbness, difficulty in speaking or understanding speech, difficulty in swallowing, difficulty in writing or reading, loss of fine motor skills such as hand tremors, loss of coordination, loss of balance, abnormal sense of taste and loss of consciousness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Brain Hemorrhage - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Hemorrhage (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Hemorrhage (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 5 and 1 respectively.Brain Hemorrhage.

Brain Hemorrhage (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Hemorrhage (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Brain Hemorrhage (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Brain Hemorrhage (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Brain Hemorrhage (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Brain Hemorrhage (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Brain Hemorrhage (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Brain Hemorrhage (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Brain Hemorrhage Overview
  • Therapeutics Development
    • Pipeline Products for Brain Hemorrhage - Overview
  • Brain Hemorrhage - Therapeutics under Development by Companies
  • Brain Hemorrhage - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Brain Hemorrhage - Products under Development by Companies
  • Brain Hemorrhage - Companies Involved in Therapeutics Development
    • Bio Products Laboratory Ltd
    • Edge Therapeutics Inc
    • F. Hoffmann-La Roche Ltd
    • Fina Biotech
    • MediPost Co Ltd
    • Pfizer Inc
    • Remedy Pharmaceuticals Inc
  • Brain Hemorrhage - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alteplase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprotinin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CN-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glyburide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • haptoglobin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05230907 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pneumostem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRC-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit tPA and uPA for Intracranial Hemorrhage - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RMP-HPE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Brain Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Brain Hemorrhage - Dormant Projects
  • Brain Hemorrhage - Discontinued Products
  • Brain Hemorrhage - Product Development Milestones
    • Featured News & Press Releases
      • Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of EG-1964 To Treat Brain Hemorrhage
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Brain Hemorrhage, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Brain Hemorrhage - Pipeline by Bio Products Laboratory Ltd, H2 2016
  • Brain Hemorrhage - Pipeline by Edge Therapeutics Inc, H2 2016
  • Brain Hemorrhage - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Brain Hemorrhage - Pipeline by Fina Biotech, H2 2016
  • Brain Hemorrhage - Pipeline by MediPost Co Ltd, H2 2016
  • Brain Hemorrhage - Pipeline by Pfizer Inc, H2 2016
  • Brain Hemorrhage - Pipeline by Remedy Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Brain Hemorrhage - Dormant Projects, H2 2016
  • Brain Hemorrhage - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Brain Hemorrhage, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top